GB201522433D0 - Cancer treatment - Google Patents

Cancer treatment

Info

Publication number
GB201522433D0
GB201522433D0 GBGB1522433.0A GB201522433A GB201522433D0 GB 201522433 D0 GB201522433 D0 GB 201522433D0 GB 201522433 A GB201522433 A GB 201522433A GB 201522433 D0 GB201522433 D0 GB 201522433D0
Authority
GB
United Kingdom
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1522433.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liverpool
Original Assignee
University of Liverpool
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liverpool filed Critical University of Liverpool
Priority to GBGB1522433.0A priority Critical patent/GB201522433D0/en
Publication of GB201522433D0 publication Critical patent/GB201522433D0/en
Priority to PCT/GB2016/053991 priority patent/WO2017103625A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
GBGB1522433.0A 2015-12-18 2015-12-18 Cancer treatment Ceased GB201522433D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1522433.0A GB201522433D0 (en) 2015-12-18 2015-12-18 Cancer treatment
PCT/GB2016/053991 WO2017103625A1 (en) 2015-12-18 2016-12-19 Cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1522433.0A GB201522433D0 (en) 2015-12-18 2015-12-18 Cancer treatment

Publications (1)

Publication Number Publication Date
GB201522433D0 true GB201522433D0 (en) 2016-02-03

Family

ID=55311264

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1522433.0A Ceased GB201522433D0 (en) 2015-12-18 2015-12-18 Cancer treatment

Country Status (2)

Country Link
GB (1) GB201522433D0 (en)
WO (1) WO2017103625A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107693509A (en) * 2017-11-22 2018-02-16 中国医药集团总公司四川抗菌素工业研究所 SB FI 26 are preparing the application in treating breast cancer medicines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358716B1 (en) * 2008-11-12 2016-01-06 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)

Also Published As

Publication number Publication date
WO2017103625A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
RS57371B1 (en) Cancer treatments
IL259996A (en) Combinations for the treatment of cancer
IL263802A (en) Cancer treatment combinations
HK1231561A1 (en) Cancer treatment
PT3576740T (en) Cancer treatment
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
GB201706451D0 (en) Cancer treatment
GB201409363D0 (en) Skin cancer treatment
HK1251794A1 (en) Cancer treatment
GB201508841D0 (en) Treatment
IL274626A (en) Cancer treatment
IL268463A (en) Cancer treatment
GB201519734D0 (en) Cancer therapy
ZA201707024B (en) Cancer treatment composition
GB201707864D0 (en) Platinum-reistant cancer treatment
HK1254687A1 (en) Combination therapy for cancer
GB201522433D0 (en) Cancer treatment
GB201503008D0 (en) Treatment
HRP20210383T8 (en) Combination therapy for cancer
GB201713852D0 (en) Cancer treatment
GB201514777D0 (en) Cancer Treatments
GB201511609D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)